Trophoblastäre Erkrankungen – eine Übersicht

Gestationsbedingte trophoblastäre Erkrankungen (GTD) bilden eine zytogenetisch und klinisch heterogene Gruppe. Sie sind durch eine Fehldifferenzierung und/oder eine Proliferation des Trophoblastepithels gekennzeichnet. Die Bestimmung von humanem Choriongonadotropin (hCG) im Serum oder Urin ist neben dem histologischen Nachweis der wichtigste Parameter zur Festlegung der Therapie, der Therapiedauer sowie der Nachsorge.

Schlüsselwörter

Trophoblastneoplasien - GTD - GTN - Diagnostik - Therapie - Methotrexat

• Literatur

• 1 Tempfer C, Horn LC, Ackermann S. et al. Gestationsbedingte und nicht gestationsbedingte Trophoblasterkrankungen. Leitlinie der DGGG (S2k-Level, AWMF-Registernummer 032/049, Februar 2019). Im Internet (Stand: 07.08.2020): https://www.awmf.org/uploads/tx_szleitlinien/032-049l_S2k_Gestationelle_nichtgestationelle_Trophoblasterkrankungen_2019-05.pdf
• 2 Akbulut M, Tosun H, Soysal ME. et al. Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature. Arch Gynecol Obstet 2008; 278: 79-84
• 3 Pezeshki M, Hancock BW, Silcocks P. et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 2004; 95: 423-429
• 4 Seckl MJ, Sebire NJ, Fisher RA. et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi39-v50
• 5 Eysbouts YK, Bulten J, Ottevanger PB. et al. Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. Gynecol Oncol 2016; 140: 70-75
• 6 Cole LA, Sutton JM, Higgins TN. et al. Between-method variation in human chorionic gonadotropin test results. Clin Chem 2004; 50: 874-882
• 7 Hoffner L, Surti U. The genetics of gestational trophoblastic disease: a rare complication of pregnancy. Cancer Genet 2012; 205: 63-77
• 8 Mangili G, Lorusso D, Brown J. et al. Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Int J Gynecol Cancer 2014; 24 (9 Suppl 3): S109-S116
• 9 Lybol C, Sweep FC, Harvey R. et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2012; 125: 576-579
• 10 Chapman-Davis E, Hoekstra AV, Rademaker AW. et al. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol 2012; 125: 572-575
• 11 Alifrangis C, Agarwal R, Short D. et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013; 31: 280-286
• 12 Barber EL, Schink JC, Lurain JR. Hepatic metastasis in gestational trophoblastic neoplasia: patient characteristics, prognostic factors, and outcomes. J Reprod Med 2014; 59: 199-203
• 13 Schmid P, Nagai Y, Agarwal R. et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009; 374: 48-55
• 14 Froeling FEM, Ramaswami R, Papanastasopoulos P. et al. Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. Br J Cancer 2019; 120: 587-594
• 15 Zhao J, Lv WG, Feng FZ. et al. Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment. Gynecol Oncol 2016; 142: 102-108
• 16 Izhar R. Aziz-un-Nisa. Prognosis of gestational choriocarcinoma at Khyber Teaching Hospital Peshawar. J Ayub Med Coll Abbottabad 2003; 15: 45-48